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OBJECTIVES The present study evaluated clinical outcomes in diabetic patients after multivessel stenting.
BACKGROUND Multivessel angioplasty studies have reported decreased survival in diabetic patients under-
going conventional balloon angioplasty compared with coronary artery bypass graft surgery
(CABG). However, several studies have demonstrated excellent procedural success and
acceptable clinical outcomes after multivessel stenting.
METHODS Multivessel stenting was performed in 689 patients with 1,639 native coronary lesions.
Patients were classified into three groups according to diabetes mellitus (DM) status: 1) no
DM (501 patients/1,200 lesions); 2) DM treated with oral agents (102 patients/235 lesions);
and 3) DM treated with insulin (86 patients/204 lesions).
RESULTS Procedural success was high overall. In-hospital CABG was higher in diabetics treated with
insulin compared with the other two groups (3.5% vs. 0.4% vs. 1.0%, p  0.02). There were
no significant differences in the incidence of in-hospital cardiac death and myocardial
infarction. Diabetic patients treated with oral agents or insulin had higher one-year target
lesion revascularization rates than non-diabetic patients (25% vs. 35% vs. 16%, p  0.001).
Lower one-year survival was observed in diabetic patients treated with either oral agents or
insulin, compared with non-diabetic patients (85% vs. 86% vs. 95%, p  0.001). On
multivariable analysis, DM was an independent predictor of one-year mortality, myocardial
infarction, and target lesion revascularization after multivessel stenting.
CONCLUSIONS Despite a high technical success rate of multivessel stenting, diabetic patients, especially those
treated with insulin, have higher in-hospital CABG, higher subsequent revascularization
rates, and lower one-year survival than non-diabetic patients. (J Am Coll Cardiol 2004;43:
1348–54) © 2004 by the American College of Cardiology Foundationt
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ihe Bypass Angioplasty Revascularization Investigation
BARI) showed that there was no significant difference in
he overall five-year survival rate between percutaneous
ransluminal coronary angioplasty (PTCA) and coronary
rtery bypass graft surgery (CABG) groups with multivessel
isease (1). However, in the subgroup of BARI patients
ith medication-treated diabetes mellitus (DM), there was
lower survival rate in the PTCA group (2). This finding
as not replicated in the BARI registry (3). More impor-
antly, coronary stents were not used in the BARI study.
See page 1355
Previous randomized trials (4,5) have demonstrated lower
estenosis rates with coronary stents compared with conven-
ional balloon angioplasty. This has resulted in an exponen-
ial increase in stent use (6). Recently, several studies (7–10)
ave shown high procedural success and an acceptable
ong-term outcome after multivessel stenting. However,
From the Cardiovascular Research Foundation, Lenox Hill Heart and Vascular
nstitute, New York, New York.
Manuscript received July 29, 2002; revised manuscript received March 28, 2003,
eccepted April 4, 2003.here is little information on short- and long-term results of
ultivessel stenting in diabetic patients, which is the group
ddressed in BARI. The present study evaluated in-hospital
nd one-year outcomes after multivessel stenting in diabetic
atients.
ETHODS
atient population. The prospective database of the Car-
iovascular Research Foundation was reviewed to identify
onsecutive patients who underwent multivessel stenting in
ative coronary lesions (1993 to 1999). Multivessel stenting
as defined as stenting in two or more major native
oronary artery territories. Lesions treated with coil stents
ere excluded because higher event rates after stenting with
oil stents have been demonstrated (11). Patients with an
cute myocardial infarction (MI) within the previous 48 h
nd lesions in arterial or vein grafts were also excluded.
here were 689 consecutive patients who underwent mul-
ivessel stenting in 1,639 native coronaries. Patients were
lassified into three groups according to the status of DM.
atients were considered to have DM if they received
nsulin or oral hypoglycemic drugs at the time of study
ntry. The 25 patients with a history of diabetes, but who
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April 21, 2004:1348–54 Multivessel Stenting in Diabetic Patientsere not taking oral hypoglycemic agents or insulin, were
ncluded in the patient group without DM, similar to the
ARI study (2). There were 501 patients (1,200 lesions)
ith no DM, 102 diabetic patients (235 lesions) treated
ith oral agents, and 86 diabetic patients (204 lesions)
reated with insulin.
rocedure. All procedures were performed after written,
nformed consent was obtained. All patients underwent
tenting according to current guidelines (12). Several
lotted-tube, corrugated, and mesh stents were used, de-
ending on lesion length, location, proximal tortuosity,
alcification, operator preferences, and/or stent availability.
fter stent implantation, angiographic optimization was
erformed using high-pressure balloon dilation to achieve
n acceptable angiographic result with 20% residual ste-
osis by a visual estimate.
All patients received aspirin 325 mg/day at least 24 h
efore the procedure and continued indefinitely. Patients
ere treated concomitantly with an additional antiplatelet
gent: either ticlopidine, 250 mg twice daily, or clopidogrel,
5 mg/day for 4 weeks.
ngiographic analysis. All cineangiograms were analyzed
sing a computer-assisted, automated edge-detection algo-
ithm (ARTREK, Quantitative Cardiac Systems, Ann Ar-
or, Michigan) by a core laboratory that was blinded to the
linical outcomes. Standard qualitative and quantitative
efinitions and measurements were used (13). The outer
iameter of the contrast-filled catheter was used as the
alibration, and the minimum lumen diameter was obtained
rom the single view that revealed the worst vessel stenosis.
linical definitions and follow-up. A dedicated Data
oordinating Center performed all data management and
nalyses. Prespecified clinical and laboratory demographic
ata were obtained from hospital charts that were reviewed
y independent research personnel who were unaware of the
bjectives of the study; accumulated data were then entered
rospectively in the data base. Q-wave MI (QMI) was
efined by the presence of new pathologic Q waves on the
lectrocardiogram. Non-QMI after stenting was defined as
reatine kinase-MB enzyme elevation at least three times
he upper normal value without new Q waves. Post-
rocedural renal failure was an increase of 25% over
aseline serum creatinine levels, with or without dialysis.
ong-term (one-year) clinical follow-up was performed by
Abbreviations and Acronyms
BARI  Bypass Angioplasty Revascularization
Investigation
CABG coronary artery bypass graft surgery
DM  diabetes mellitus
MI  myocardial infarction
PTCA  percutaneous transluminal coronary angioplasty
QMI  Q-wave myocardial infarction
TLR  target lesion revascularizationither telephone contact or an office visit. The occurrence of iajor late clinical events was recorded, including death (all-
ause), MI, and target lesion revascularization (TLR); these
ere adjudicated by accompanying source documentation.
tatistical analysis. Statistical analysis was performed us-
ng Statistical Analysis Systems (SAS Institute Inc., Cary,
orth Carolina) by a dedicated data analysis center. Data
ere expressed as proportions or mean values  SD.
ontinuous variables were compared using analysis of vari-
nce. Categorical variables were compared with chi-square
tatistics. A p value 0.05 was considered significant.
Kaplan-Meier estimates were used to report cumulative
ates of survival, MI, TLR, and event-free survival. Kaplan-
eier curves were compared using the log-rank test. Step-
ise logistic regression with entry and stay criteria of 0.10
as used to find independent predictors of one-year mor-
ality, MI, and TLR. Diabetic status was forced into all
odels; candidate variables for inclusion in the models were
emale gender, age in years, current smoking, history of
erebrovascular event, preexisting chronic renal insuffi-
iency, post-procedural renal failure, previous PCI, previous
I, hypertension, peripheral vascular disease, and left
nterior descending coronary artery and ostial lesion loca-
ion. Data on reference vessel diameter was incomplete in
0% of patients; therefore, it was not included in the
odels.
ESULTS
aseline and procedural characteristics. Patient demo-
raphics are presented in Table 1. There were more women
n the diabetic group than in the non-diabetic group. A
igher proportion of diabetic patients had a history of
ypertension, chronic renal failure (baseline serum creati-
ine value 2.0 mg/dl or receiving dialysis), peripheral
ascular disease, and cerebrovascular events. A higher inci-
ence of congestive heart failure and a lower left ventricular
jection fraction were observed in diabetic patients treated
ith oral agents, as compared with the other two groups.
Table 2 shows lesion and procedural characteristics.
here were more left main and ostial lesions in diabetic
atients treated with oral agents. Glycoprotein IIb/IIIa
nhibitors were used in 10% of all groups. More than half
f non-diabetic patients and diabetic patients treated with
ral agents and three-fourths of insulin-treated diabetics
nderwent stenting of three or more lesions.
Quantitative angiographic results are presented in Table
. There was a significant difference in reference vessel
iameter (smaller in diabetic patients treated with insulin).
efore and after the procedure, the minimum lumen diam-
ter, diameter stenosis, and lesion length were not signifi-
antly different among the three groups.
rocedural and in-hospital outcomes. Overall procedural
uccess was high in all three groups (Table 4). There were
o significant differences in the incidence of QMI and
on-QMI. A higher in-hospital CABG rate was observedn diabetic patients treated with insulin, as compared with
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Multivessel Stenting in Diabetic Patients April 21, 2004:1348–54he other two groups. There was no significant difference in
he incidence of cardiac death among the three groups.
ne-year outcomes. Lower one-year survival was ob-
erved in diabetic patients treated with either oral agents or
nsulin, as compared with non-diabetic patients (85% vs.
6% vs. 95%, p 0.001) (Fig. 1). There was a trend toward
ore MIs during follow-up in diabetic patients treated with
ither oral agents or insulin (9.2% vs. 8.1% vs. 3.9%, p 
.057). Diabetic patients treated with oral agents and
nsulin had higher one-year TLR rates, as compared with
on-diabetic patients (25% vs. 35% vs. 16%, p  0.001).
ower event-free survival, defined as freedom from death,
MI, and TLR, was observed in diabetic patients treated
Table 1. Baseline Characteristics
No DM
(n  501)
Age (yrs) 64  12
Male (%) 76
Hypertension (%) 56
Hypercholesterolemia (%) 70
Current smoking (%) 15
Family history (%) 57
Chronic renal failure (%) 6.2
Peripheral vascular disease (%) 11
History of CVA (%) 9.4
Previous MI (%) 47
Congestive heart failure (%) 5.6
LVEF (%) 49  13
LVEF 50% (%) 30
Previous PCI (%) 33
Previous CABG (%) 30
Unstable angina (%) 75
Data are presented as the mean value  SD or percentage o
CABG  coronary artery bypass grafting; CVA 
insulin-dependent DM; LVEF  left ventricular ejection
dependent DM; PCI  percutaneous coronary intervention.
Table 2. Angiographic and Procedural Charact
Restenotic lesion (%)
Treated vessel (%)
LAD
RCA
LCx
LMCA
Ostial lesion (%)
Patients with proximal disease (%)
Patients with left-main or proximal LAD lesion (%)
Patients with 1 type C lesion (%)
Patients with 1 total occlusion (%)
Glycoprotein IIb/IIIa inhibitor (%)
Stents/patient
Stents/lesion
Stent length (mm)
No. of lesions (%)
2 lesions
3 lesions
Data are presented as the percentage of subjects or mean va
LAD  left anterior descending artery; LCx  left circucoronary artery; other abbreviations as in Table 1.ith either oral agents or insulin (63% vs. 60% vs. 79%, p
.001) (Fig. 2).
Multivariate analysis demonstrated that DM (p 0.001),
ost-procedural renal failure (p  0.01), old age (p  0.01),
eft anterior descending coronary artery lesions (p  0.04),
nd peripheral vascular disease (p 0.04) were independent
redictors of one-year mortality after multivessel stenting.
iabetes mellitus (p  0.02) and previous CABG (p 
.02) were independent predictors of MI during follow-up.
ultivariate predictors of TLR were DM (p  0.001),
ypertension (p  0.02), and a previous percutaneous
oronary intervention (p  0.03); baseline renal failure and
ost-intervention renal failure were not significant.
NIDDM
(n  102)
IDDM
(n  86) p Value
66  10 63  11 0.17
61 52  0.001
77 77  0.001
67 71 0.79
12 11 0.39
55 69 0.10
13 20  0.001
31 40  0.001
13 21 0.006
54 48 0.41
14.7 9.3 0.005
41  15 46  13  0.001
47 39 0.01
31 45 0.08
42 30 0.06
80 81 0.34
ects.
rovascular attack; DM  diabetes mellitus; IDDM 
n; MI  myocardial infarction; NIDDM  non–insulin-
ics
No DM
 1,200)
NIDDM
(n  235)
IDDM
(n  204) p Value
8.6 6.4 11 0.26
28 26 31 0.49
29 26 29 0.58
36 35 34 0.84
7.3 13 5.9 0.005
8.3 13 6.9 0.03
71 77 67 0.37
45 50 36 0.15
42 43 40 0.88
1.4 0 0 0.56
8.0 8.8 7.0 0.90
2.8  1.1 2.8  1.4 2.9  1.2 0.91
1.2  0.5 1.2  0.5 1.1  0.4 0.47
9.6  8.9 18.8  8.7 19.5  8.1 0.43
44 44 29 0.03
56 56 71 0.03
SD.
artery; LMCA  left main coronary artery; RCA  rightf subj
cereb
fractioerist
(n
1
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April 21, 2004:1348–54 Multivessel Stenting in Diabetic PatientsISCUSSION
he present study demonstrated high technical success rates
or multivessel stenting in diabetic patients treated with
ither oral agents or insulin. However, a higher incidence of
n-hospital CABG, a higher one-year revascularization rate,
nd a lower one-year survival rate were observed in diabetic
atients, especially those treated with insulin, compared
ith non-diabetic patients.
ercutaneous coronary intervention in diabetic patients
ith multivessel disease. Previous randomized trials
1,14–16) demonstrated that there was no significant dif-
erence in overall survival rates between the PTCA and
ABG groups of patients with multivessel disease. In the
ARI study, 1) the in-hospital event mortality rates for
TCA and CABG were 1.1% and 1.3%, respectively (p 
S); 2) the respective in-hospital QMI rates were 2.1% and
.6% (p  0.01); and 3) the overall five-year survival rates
ere 89% in patients assigned to CABG and 86% in those
reated with PTCA (p  0.19) (1). However, in those
tudies (1,14–16), the TLR rate was higher in the PTCA
roup (range 37% to 55%) than in the CABG group (range
% to 13%). In addition, the need for in-hospital CABG in
he PTCA group was relatively high (range 5% to 10%).
Diabetes mellitus has been shown to have a negative
mpact on mortality and morbidity after catheter-based
nterventions, as well as CABG, although diabetic patients
onstitute up to 26% of patients presenting for such proce-
ures (2,17,18). Previous studies (18) demonstrated that
alloon angioplasty to treat coronary artery disease in
iabetic patients has been associated with an increased rate
Table 3. Quantitative Angiographic Results
No DM
(n  1,200)
Before procedure
Reference (mm) 2.94  0.68
MLD (mm) 1.10  0.63
Stenosis (%) 62  21
Lesion length (mm) 11.0  8.9
After procedure
Reference (mm) 3.07  0.63
MLD (mm) 2.84  0.75
Stenosis (%) 7  18
Data are presented as the mean value  SD.
MLD  minimum lumen diameter; other abbreviations
Table 4. In-Hospital Outcomes of Patients/Le
No DM
(n  560/1,428)
Angiographic success (%) 99.8
Abrupt closure (%) 1.3
QMI (%) 0
Non-QMI (%) 27
CABG (%) 0.4
All-cause mortality (%) 0.4
Cardiac mortality (%) 0.2
Renal insufficiency (%) 2.0NA  not applicable; QMI  Q-wave myocardial infarction; othf acute complications and a higher restenosis rate, com-
ared with non-diabetic patients. In a subgroup analysis of
he BARI trial in diabetic patients treated with insulin or
ral hypoglycemic agents (2), the respective in-hospital
vent rates for PTCA and CABG were 0.6% and 1.2% for
ortality (p  NS) and 1.8% and 5.8% for QMI (p  NS).
owever, those patients had a significantly lower five-year
urvival rate with multivessel angioplasty compared with
ABG (66% vs. 81%, p  0.003), and the corresponding
ardiac mortality rates were 20.6% and 5.8%. This led to the
otion that coronary angioplasty may not be a suitable
herapy for multivessel disease in patients with DM (19).
owever, those randomized trials were conducted before
he stent era.
tenting in diabetic patients with multivessel disease.
ince randomized studies (4,5) have demonstrated higher
arly success and lower restenosis rates in selected lesions,
tents are used in up to 80% of interventional procedures
orldwide (6). Recently, several studies (7–10) have shown
igh early success and acceptable long-term results with
ultivessel stenting. Moussa et al. (7) demonstrated a
rocedural success rate of 97% in 100 patients who under-
ent multivessel stenting. The in-hospital mortality rate
as 1%, the in-hospital CABG rate was 2%, and the QMI
ate was 2%. During follow-up, mortality and CABG rates
ere 4% and 2%, respectively, and angiographic restenosis
as observed in 22% of lesions and 37% of patients. In 398
atients with multivessel stenting, Kornowski et al. (8)
emonstrated a procedural success rate of 96% and a
ospital mortality rate of 0.5%. In-hospital CABG was
IDDM
n  235)
IDDM
(n  204) p Value
0  0.62 2.66  0.57 0.046
0  0.57 1.02  0.57 0.81
9  19 61  18 0.44
.5  8.7 10.5  7.4 0.93
4  0.61 2.83  0.60 0.07
1  0.68 2.64  0.65 0.20
8  16 4  28 0.67
able 1.
NIDDM
n  114/284)
IDDM
(n  81/213) p Value
99.0 100 0.47
0.4 0 0.13
0 0 NA
28 21 0.51
1.0 3.5 0.02
1.0 2.3 0.08
1.0 1.2 0.18
2.0 8.2 0.01N
(
2.8
1.1
5
10
2.9
2.7sions
(er abbreviations as in Table 1.
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Multivessel Stenting in Diabetic Patients April 21, 2004:1348–54erformed in 2% of patients, and QMI was observed in
.9%. During follow-up, the mortality and CABG rates
ere 0.7% and 7.9%, respectively. Target vessel revascular-
zation was necessary in 15% of lesions.
There is little information on short- and long-term
utcomes after multivessel stenting in diabetic patients. The
resent study demonstrated that, despite a high angio-
raphic success rate, multivessel stenting in diabetic pa-
ients, especially those treated with insulin, was associated
ith higher in-hospital CABG, long-term mortality, and
LR rates, as compared with non-diabetic patients. The
ate of peri-procedural non-QMI was 28% in the entire
opulation and did not differ by diabetic status. This likely
igure 1. Actuarial survival curves after multivessel stenting. Lower surviv
gents or insulin, compared with non-diabetic patients.
igure 2. Actuarial event-free survival curves after multivessel stenting. Low
ith either oral agents or insulin.eflects the fact that this was a high-risk population with a
arge number of lesions stented. In addition, the low use of
lycoprotein IIb/IIIa agents may have contributed to the
arge number of peri-procedural non-QMIs. Despite this,
n-hospital QMI rates were acceptable.
It has long been appreciated that DM is a major risk
actor for the development of atherosclerosis, resulting in a
ide variety of cardiovascular dysfunction and complica-
ions (20). Based on high angiographic success and low
cute closure rates, the higher in-hospital CABG rate may
e associated with incomplete revascularization due to
iffusely diseased coronary arteries. The high long-term
dverse cardiac event rate may reflect the development of
observed in patients with diabetes mellitus (DM) treated with either oral
nt-free survival is observed in patients with diabetes mellitus (DM) treatedal iser eve
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April 21, 2004:1348–54 Multivessel Stenting in Diabetic Patientsew lesions, progression of untreated less severe lesions, and
ncomplete revascularization due to diffusely diseased coro-
ary arteries (21). It may also be associated with rates of
o-morbidities, including chronic renal failure, which is
ssociated with a high event rate after percutaneous coro-
ary intervention (22).
Coronary arteries of treated diabetic patients tend to be
maller, probably due to more diffuse disease (18,23). This
ay partly explain a high restenosis rate in diabetic patients
17,23). Furthermore, high restenosis rates in diabetic
atients probably result from complex hormonal and bio-
hemical alterations associated with DM (24). These may
esult in accelerated intimal hyperplasia after stenting (25).
Recently, randomized studies have demonstrated long-
erm outcomes in patients with multivessel disease treated
ith multivessel stenting compared with CABG (9,10).
he Arterial Revascularization Therapies Study (ARTS)
howed no difference in mortality rate at one-year follow-up
etween the two groups (9). On the other hand, the Estudio
andomizado Argentino de angioplastia vs CIrugia
ERACI II) demonstrated a lower one-year mortality rate in
he multivessel stenting group compared with the CABG
roup (10). In both studies, repeat revascularization proce-
ures were performed more frequently in the multivessel
tenting group.
The baseline characteristics in the present study were
orse than those in the multivessel angioplasty or stenting
rm of BARI and ARTS (Table 5). Because this study was
real-world clinical study, not a randomized study, the
hysician, patient, and family might choose multivessel
tenting for patients with more complex lesions than the
atients included in randomized studies. Thus, it may not
e justified to compare the results after multivessel stenting
n diabetic patients in the current report with those after
ABG in randomized studies. Furthermore, in the BARI
egistry, there were no significant differences in the long-
erm mortality of diabetic patients between the PTCA and
ABG groups (3). Finally, drug-eluting stents may alter
able 5. Baseline Characteristics of Patients Treated With
ultivessel Angioplasty or Stenting
BARI ARTS
Present
Study
emale (%) 27 23 29
revious MI (%) 54 56 52
ongestive heart failure (%) 9 0 7.5
ypertension (%) 49 45 62
iabetes mellitus (%) 24 19 31
reated diabetics (%) 19 NA 27
1 vessel with proximal disease (%) 68 NA 71
1 type C lesion (%) 38 NA 42
1 total occlusion (%) 36 3 1
ean ejection fraction (%) 57.1 61 47
jection fraction 50% (%) 23 NA 34
RTS  Arterial Revascularization Therapies Study; BARI  Bypass Angioplasty
evascularization Investigation study; MI  myocardial infarction; NA  not
vailable.his balance in favor of percutaneous revascularization (26).tudy limitations. First, this is a retrospective analysis
ather than a prospective, randomized clinical trial designed
o assess the efficacy of stenting in patients with multivessel
isease. Therefore, baseline characteristics were worse in
atients with DM, especially those treated with insulin.
ffsetting this limitation, the data were collected prospec-
ively by independent monitors and entered into a dedicated
atabase, and an independent core laboratory interpreted all
ngiograms. Furthermore, this represents conditions of
eal-world experience, rather than the conditions typically
ncluded in randomized trials. Second, detailed information
n diabetic status, such as fasting glucose values or levels of
lycosylated hemoglobin, was not collected. Previous studies
27,28) demonstrated the importance of glycemic control in
educing cardiovascular mortality and morbidity in diabetic
atients. In addition, detailed information on lipid status
as not available, although the incidence of hypercholester-
lemia was not different among the three groups. Third,
lycoprotein IIb/IIIa inhibitors were used at a rate of10%
n all groups. Recently, lower long-term mortality and TLR
ates have been shown in diabetic patients who received
bciximab during percutaneous coronary intervention (29)
r stenting (30). This may partially explain the high event
ates during follow-up in this study. Fourth, the current
nalysis does not include patients undergoing multivessel
tenting in saphenous vein grafts. Because this patient
opulation may differ in their baseline demographics and
linical outcomes, we have elected to address the issue of
ultivessel stenting in vein grafts in a separate study.
inally, the reference vessel diameter was not assessed in
0% of patients. Diabetics often have significantly smaller
essels, and this may have been an important confounder in
he higher rate of TLR reported.
onclusions. Despite a high technical success rate of
ultivessel stenting, diabetic patients, especially those
reated with insulin, have higher in-hospital CABG, lower
urvival, and higher subsequent revascularization procedure
ates at one-year clinical follow-up, compared with non-
iabetic patients. If multivessel stenting is performed in
reated patients with DM, meticulous post-procedural scru-
iny and medical management are warranted.
eprint requests and correspondence: Dr. George D. Dangas,
ardiovascular Research Foundation, Lenox Hill Heart and Vas-
ular Institute, 55 East 59th Street, 6th Floor, New York, New
ork 10022. E-mail: gdangas@crf.org.
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